Adding the 5-Alpha-Reductase Inhibitor: Whose Prostate Earns It
Two men on tamsulosin for benign prostatic hyperplasia, both being considered for an added 5-alpha-reductase inhibitor. The drug is the same; the argument for using it is not — one man's numbers make the case, the other's don't quite, and he has already told the team what that should mean.
R.M., 66, spent thirty years surveying county roads before retiring, and still keeps a table saw running most weekends building furniture for his grandchildren — work that has him on his feet and, increasingly, running to the bathroom in the middle of it. Nocturia has crept up to four times a night over the past year, and his stream, by his own description, "used to clear a urinal in ten seconds and now takes half a minute." He started tamsulosin four months ago with his primary care physician; it helped some, but not enough that he stopped setting an alarm for a 2 a.m. bathroom trip. His only other diagnosis is well-controlled hypertension on lisinopril, present for a decade without kidney involvement — nothing in his history suggests a second explanation for the urinary symptoms competing with the obvious one.
On exam his prostate is symmetrically enlarged and non-nodular, estimated at 58mL by ultrasound — nearly double the CombAT trial's own 30mL enrollment threshold for its higher-risk population. His PSA is 3.8ng/mL, consistent with gland size rather than concerning on its own, and sits well above that same trial's 1.5ng/mL entry floor. His AUA symptom score is 19 — the top of the moderate band, one point below the severe range — and his post-void residual measures 110mL — itself an independent marker MTOPS' subgroup analysis tied to higher progression risk in men who already carry his volume and PSA profile. Three converging numbers, all pointing the same direction, are what bring the team to the question of whether tamsulosin alone is still the right amount of treatment for him. Nothing about his blood pressure control changes that calculus — the question in front of the team is entirely about the prostate. What makes his case worth pausing on, rather than simply escalating on reflex, is that none of his three findings arrived in isolation: the volume was measured on the same ultrasound that produced the residual, the PSA was drawn the same week, and all three point the same direction rather than one outlier dragging an otherwise reassuring picture. A clinician reading any one of these numbers alone might reasonably wait; reading all three together is a different exercise entirely, and it's the reason the conversation has moved from "watch and see" to an actual decision point at today's visit.
Reviewing his numbers against the trial that studied them
His volume and PSA aren't just consistent with the higher-risk group CombAT enrolled — they're inside it with room to spare, and that trial showed real reduction in retention and surgery risk from adding dutasteride to tamsulosin in men who look like him. I'd start it now, before a first retention episode does the deciding for us.
I'm not disputing the population match. What I'd weigh against it is the timeline: the curves in that trial don't meaningfully separate from tamsulosin alone for a year or more, and the sexual side effects — libido, erectile function, ejaculation — start on day one and don't reliably resolve in every man who gets them. He's 66, active, still working with his hands. That's a real, immediate cost against a benefit that mostly protects him from something years off.
"Room to spare" cuts both ways — a bigger margin over threshold means a more confident population match, but it doesn't shorten how long the drug takes to start paying that match off.
There's a third number neither of you has weighted yet. MTOPS' subgroup data found elevated PVR was its own independent progression marker in men who already met the volume and PSA threshold — not a restatement of the same risk, a second one. His 110mL isn't decisive alone, but stacked on top of a 58mL gland and a 3.8 PSA, it's three converging signals, not two. I'd rather accept the timeline cost now than watch a third marker confirm what the first two were already telling us.
Agreed: start dutasteride 0.5mg daily added to his existing tamsulosin, with explicit counseling on sexual side effects and the one-to-two-year timeline before benefit separates meaningfully from monotherapy.
Not agreed: whether to set a formal 6-month interim check of his AUA score and PVR given how bothersome his baseline symptoms already are, or to commit to the trial's own longer timeline before judging whether the combination is working. The urologist wants to hold the full course; the primary care physician wants an earlier look given how much his quality of life is already affected.
T.O., 61, remarried eight months ago after his first wife died three years back, and is still, in his own words, "getting used to having someone to be a whole person for again." His urinary symptoms — daytime frequency, a weaker stream, occasional urgency — have been present for about two years and are moderate, not severe: an AUA symptom score of 14. Tamsulosin, started six weeks ago, has taken the edge off. What brought the 5-ARI question to the table isn't his symptoms escalating; it's a routine follow-up where his physician raised it as the next step, and T.O. immediately asked whether it was the drug "that can mess with things" — he'd read about sexual side effects online and wanted to know before agreeing to anything.
His prostate volume is 27mL and his PSA is 1.3ng/mL — both below the 30mL and 1.5ng/mL entry thresholds CombAT used to define the higher-risk population Patient A's numbers sat well inside. MTOPS is the more awkward comparison, because it set no volume or PSA floor at all and would have enrolled him: its trial-level result therefore does describe men like him, but its own volume-stratified analysis found finasteride reduced clinical progression significantly in men with prostates of 30mL or more and not in those below that mark — which is where he sits. His post-void residual is 40mL, unremarkable. He has been direct about his priorities: he and his wife have a full, active life together, and he does not want to trade a meaningful chance of diminished sexual function for what he understands, correctly, to be a smaller and less certain benefit than a man with his numbers would get. He is otherwise healthy — no diabetes, no cardiovascular disease, no medications besides the tamsulosin — which is part of why the conversation feels different to him: there is no competing health problem making the decision for him, only a genuine trade-off he wants to make with his eyes open.
The same drug, a different case for it
His volume and PSA sit below what CombAT actually enrolled. MTOPS is the harder one for me, because it set no volume or PSA floor and would have taken him — but its own volume-stratified analysis found finasteride's benefit on clinical progression in men at or above 30mL and not below it. So the benefit we're citing for a man like Patient A hasn't been demonstrated in a man built like this one, and in the one trial that did enroll him, the subgroup he belongs to is the one where it didn't reach significance.
A subgroup that didn't reach significance isn't the same finding as a subgroup where the drug did nothing — MTOPS wasn't powered to settle the sub-30mL stratum on its own. Androgen suppression, symptom reduction, and gland shrinkage operate on a continuum, and larger glands simply respond more. No guideline sets a hard floor below which the drug is inert. Some real benefit is still plausible here, offered honestly as smaller than what Patient A could expect.
I'd call that a mechanistic argument, not a demonstrated one — plausible isn't the same claim as shown, and the honest version of your own point still concedes we're extrapolating.
Then let's not settle this as a population argument at all. Give him the honest magnitude difference — smaller, less certain benefit than a man with Patient A's numbers — and he's already told us what he does with that information. He asked the question before we even framed the choice. That's not a patient we talk into anything; that's a patient whose stated priority should decide it once he has the real picture.
Agreed: continue tamsulosin monotherapy, hold the 5-ARI, and reassess his AUA score and PVR in six months. The magnitude-versus-Patient-A conversation was had directly and documented.
Not agreed: whether the six-month reassessment should be triggered by symptoms alone or should also include a routine repeat PVR regardless of how he's feeling, since some progression can be silent even when a patient reports no change.